Vor Biopharma Stock Alpha and Beta Analysis
| VOR Stock | USD 13.08 0.55 4.39% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vor Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vor Biopharma over a specified time horizon. Remember, high Vor Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vor Biopharma's market risk premium analysis include:
Beta 1.49 | Alpha (0.99) | Risk 9.54 | Sharpe Ratio (0.12) | Expected Return (1.17) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Vor Biopharma Backtesting, Vor Biopharma Valuation, Vor Biopharma Correlation, Vor Biopharma Hype Analysis, Vor Biopharma Volatility, Vor Biopharma History and analyze Vor Biopharma Performance. Vor Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vor Biopharma market risk premium is the additional return an investor will receive from holding Vor Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vor Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vor Biopharma's performance over market.| α | -0.99 | β | 1.49 |
Vor Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vor Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how Vor Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vor Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Vor Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vor Biopharma shares will generate the highest return on investment. By understating and applying Vor Biopharma stock market price indicators, traders can identify Vor Biopharma position entry and exit signals to maximize returns.
Vor Biopharma Return and Market Media
The median price of Vor Biopharma for the period between Thu, Oct 2, 2025 and Wed, Dec 31, 2025 is 15.82 with a coefficient of variation of 54.57. The daily time series for the period is distributed with a sample standard deviation of 10.76, arithmetic mean of 19.71, and mean deviation of 9.5. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Reprogrammed Interchange Llc Sells 1,400 Shares of Vor Biopharma Stock | 10/06/2025 |
2 | Disposition of 14336 shares by Reprogrammed Interchange Llc of Vor Biopharma at 34.3391 subject to Rule 16b-3 | 10/08/2025 |
3 | Disposition of 15042 shares by Reprogrammed Interchange Llc of Vor Biopharma at 32.4052 subject to Rule 16b-3 | 10/09/2025 |
4 | Disposition of 2334 shares by Reprogrammed Interchange Llc of Vor Biopharma at 33.0873 subject to Rule 16b-3 | 10/13/2025 |
5 | Disposition of tradable shares by Ra Capital Management, L.p. of Vor Biopharma at 31.17 subject to Rule 16b-3 | 10/15/2025 |
6 | Disposition of 11616 shares by Reprogrammed Interchange Llc of Vor Biopharma at 30.0535 subject to Rule 16b-3 | 10/20/2025 |
7 | Disposition of 53345 shares by Ra Capital Management, L.p. of Vor Biopharma at 28.01 subject to Rule 16b-3 | 10/24/2025 |
8 | Why Vor Biopharma Inc. stock could benefit from AI revolution - July 2025 PostEarnings Safe Entry Zone Tips - newser.com | 11/05/2025 |
9 | Disposition of 33842 shares by Reprogrammed Interchange Llc of Vor Biopharma at 31.9181 subject to Rule 16b-3 | 11/14/2025 |
10 | Will Vor Biopharma Inc. stock attract more institutional investors - newser.com | 11/19/2025 |
11 | Wedbush Predicts Vor Biopharmas Q4 Earnings - MarketBeat | 11/28/2025 |
12 | Disposition of 4164831 shares by Kress Jean-paul of Vor Biopharma at 17.8 subject to Rule 16b-3 | 12/05/2025 |
13 | Vor Biopharma Now Covered by Analysts at JPMorgan Chase Co. | 12/09/2025 |
14 | Vor Biopharmas Surge New Opportunities - StocksToTrade | 12/16/2025 |
15 | Insider Trading | 12/18/2025 |
16 | VOR JP Morgan Lowers Price Target While Maintaining Overweight Rating VOR Stock News - GuruFocus | 12/19/2025 |
17 | Vor Biopharma Inc. Sees Large Growth in Short Interest - MarketBeat | 12/24/2025 |
18 | Gap Down Is Vor Biopharma Inc stock positioned well for digital economy - July 2025 Fed Impact AI Powered BuySell Recommendations - moha.gov.vn | 12/29/2025 |
About Vor Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vor or other stocks. Alpha measures the amount that position in Vor Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Vor Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Vor Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vor Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vor Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vor Biopharma. Please utilize our Beneish M Score to check the likelihood of Vor Biopharma's management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Vor Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.